Introduction
The association between increased nuchal translucency (NT) in the first trimester and chromosomal aberrations is well documented 1, 2, 3 . However, NT is increased in 4.4% of euploid fetuses 2 . These fetuses have been reported to be at increased risk of adverse pregnancy outcome, e.g., structural abnormalities, particularly cardiac defects, genetic syndromes, and fetal loss 4−18 . Most of the studies reporting on an association between increased NT and adverse outcome had no control group 4, 9−15, 17, 18 , which makes it difficult to interpret their results, because the prevalence of adverse outcome among fetuses with increased NT (i.e., the positive predictive value of increased NT) depends entirely on the study population. Accordingly, the reported prevalence of adverse outcome among fetuses with increased NT varies widely 4, 5, 8−18 . Two of the three published studies that did have a control group were performed in high-risk pregnancies 8, 16 .
The aim of our study was to estimate the magnitude of a possible increase in risk of adverse outcome in fetuses with normal karyotype and increased NT in an unselected pregnant population, and to determine how well NT measurements can distinguish between fetuses with normal and adverse outcome.
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Subjects and methods
Study design
Our population is a subgroup of pregnancies in the Swedish NUPP-trial (NUPP is an abbreviation for NackUPPklarning, which is Swedish for nuchal translucency), which has been described in a previous publication 19 . This national multi-center trial involved eight Swedish hospitals and included 39 572 unselected pregnancies. It was approved by the Ethics
Committees at the Karolinska Institute in Stockholm, and those of the Medical Faculties of Lund University and Uppsala University. Those who consented to take part were randomized to a routine ultrasound examination either at 12 -14 gestational weeks or at 18 weeks. The 12-week scan included NT screening for Down's syndrome. The present study includes those pregnancies that were randomised to a routine ultrasound examination at 12 -14 weeks with at least one living fetus at the routine scan and information available about the result of the NT measurement. Exclusion criteria are loss to follow-up, chromosomal abnormality verified by karyotyping, or no information on karyotype in a fetal loss. The karyotype was considered normal on the basis of normal results of genetic testing or absence of stigmata of chromosomal aberration at pediatric examination of a living newborn.
All midwives and obstetricians were certified by the Fetal Medicine Foundation (FMF) as being competent to perform NT screening for chromosomal anomalies. The quality of our NT measurements was regularly checked by the FMF. The 12-week routine scan included pregnancy dating, scrutiny of fetal anatomy, and measurement of NT in accordance with the technical guidelines published by the FMF, the risk of fetal aneuploidy being calculated using the FMF software 20 . In clinical practice a risk of trisomy 21 ≥1:250 was regarded as increased. Women at increased risk of fetal chromosomal anomaly because of increased NT, a fetal structural anomaly detected at any scan during pregnancy, or a history suggesting an 5 increased risk, e.g., a previous pregnancy where the fetus had a chromosomal anomaly, were offered fetal karyotyping. Information on pregnancy outcome was retrieved from delivery records, from departments of neonatology, pediatric cardiology, pediatric surgery, neurosurgery, plastic surgery, genetics and pathology providing services to the hospitals involved, and from the National Registry of Congenital Anomalies.
Classification of congenital malformations
For statistical purposes fetuses and newborns with more than one malformation were assigned one main malformation diagnosis. Congenital heart malformations diagnosed within the first 12 months of life, and other types of malformation diagnosed (or suspected and later confirmed) before the baby was dismissed from postnatal care are included. Malformations were grouped into four categories according to their likely clinical consequences 21 . These groups were modified after a proposal by the Royal College of Obstetrics and Gynecology (RCOG) in 1997 22 . The categories were 1) lethal malformations 2) severe malformations, i.e., malformations associated with possible survival and severe immediate or long-term morbidity 3) malformations of intermediate severity, i.e., malformations associated with short-or longterm morbidity of moderate severity 4) minor malformations, i.e., malformations or abnormalities with minor morbidity or only occasional long-term morbidity. All heart malformations except isolated atrial and ventricular septal defects, and isolated valve disorders, were regarded as major heart defects and were classified as severe malformations.
Classification of fetal loss
Stillbirth <28 weeks of pregnancy was defined as miscarriage, and stillbirth ≥28 weeks of pregnancy as intrauterine fetal death. Perinatal death included intrauterine death ≥28 weeks of pregnancy, intrapartum death, and death within 7 days of birth. In Sweden, termination of pregnancy is rarely allowed >22 weeks of pregnancy.
Classification of adverse outcome
6
Adverse outcome was defined as miscarriage, termination of pregnancy, perinatal death, or live birth of a baby with a malformation of at least intermediate severity.
Statistical analysis
Fetuses were defined as being at increased risk of adverse outcome using the following NT 
Results
Of 19 
Total adverse outcome (malformation or fetal loss or both)
The rate of adverse outcome was 2.7% (441/16 260). Sensitivity, false positive rate, positive predictive value, and positive and negative likelihood ratios of increased NT with regard to total adverse outcome are presented in Table 1 . Increased NT significantly increased the risk of adverse outcome, and the risk increase rose with increasing NT. NT ≥3mm increased the likelihood of adverse outcome approximately six-fold, NT≥ 3.5mm increased it approximately 15-fold, and NT ≥ 4.5mm increased it approximately 30-fold. For all NT cutoffs the negative predictive value was high (≥ 97%).
Fetal malformations
Among 16 260 fetuses we found 772 congenital malformations, 297 of these being minor.
The remaining 475 congenital defects were found in 333 fetuses/babies, of which 15 had a 8 multiple malformations sequence, 18 had a malformed heart consisting of at least two different cardiovascular malformations but no extra-cardiac malformations, and 24 had anomalies in two or three organ systems ( For all types of fetal loss, the negative predictive value was > 99% for all cut-offs. There 
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Discussion
We have estimated the magnitude of increase in risk of adverse outcome in fetuses with normal karyotype and increased NT. NT ≥ 3.0mm increased the odds of adverse outcome 6-fold, the odds of lethal or serious malformation 15-fold, the odds of termination of pregnancy in malformed fetuses 9-fold and the odds of termination of pregnancy in normally formed fetuses almost 50-fold. The odds for these adverse outcomes increased with increasing NT.
We found no association between increased NT and perinatal death and only a weak association between increased NT and miscarriage. The low sensitivity, the high negative likelihood ratios and the small areas under the ROC curves illustrate that NT cannot reliably discriminate between favorable and unfavorable outcome in fetuses with normal karyotype.
Therefore NT measurement is not a good screening method for fetal malformation or other adverse pregnancy outcome in fetuses with normal karyotype. Our results of using NT measurement as a screening method specifically for fetal heart malformations have been reported separately 23, 24 .
Our study differs from most other studies that have examined a possible association between increased NT and adverse pregnancy outcome 4, 5, 8−18 in that each adverse outcome studied was clearly defined and in that we had a control group of fetuses with normal NT.
Most other studies -also those with a control group -lack a clear definition of which anomalies were classified as malformations 5 Table 4 . In all studies, increased NT increased the odds of malformation, miscarriage and termination of pregnancy. In none did increased NT change the odds of perinatal/neonatal death. It is interesting to note that the positive likelihood ratios of increased NT with regard to miscarriage are similar in all studies, despite two studies having been performed in high risk populations and two in unselected populations, and that the positive likelihood ratio of NT ≥3 mm with regard to malformation in our study of an unselected population is similar to that in a study of a high-risk population (Table 4) . However, it is important to bear in mind that the true association between increased NT and spontaneous fetal loss is almost certainly not reflected in the results of our study or in those cited 5, 8, 16 , because in all studies termination of pregnancy interfered with the spontaneous loss rate. Had there been no terminations of pregnancy, the association between increased NT and spontaneous fetal loss might have been completely different. Amniocentesis/chorionic villus sampling may have affected the apparent spontaneous loss rate, too. In no study did normal NT substantially decrease the odds of adverse outcome.
In our study increased NT increased the risk of termination of pregnancy among malformed fetuses, probably as a consequence of the association between increased NT and lethal and severe malformations. It is thought-provoking that increased NT increased the risk of termination of pregnancy also among fetuses with no known malformation. We are aware that three women terminated their pregnancy because they worried about the increased risk of trisomy 21 that had been calculated on the basis of an NT measurement, despite amniocentesis having shown normal karyotype and despite no malformation having been detected at ultrasound examination. There may have been additional similar cases among the losses excluded, where the reason for termination was not known in every case. This highlights the difficulties with risk information and emphasizes the importance of giving wellbalanced information both when women are first offered NT screening for Down's syndrome and when the screening result is communicated to them.
Studies without a control group can report nothing but the prevalence of the outcome studied. This corresponds to the positive predictive value of increased NT 4, 9−15, 17, 18 . It is impossible to know if the reported prevalences are higher than expected, particularly in those studies that seem to have been performed in high-risk pregnancies 10, 11, 14, 17 or where the study population was not clearly described 4, 12, 18 . Nonetheless, with one exception 4 , the prevalences of malformations in fetuses with increased NT reported in studies without a control group do seem higher than expected (9.5%-30.3% versus the expected 2-3% in an Our study shares with other similar studies the weakness of not all fetuses lost having undergone autopsy for ascertainment of fetal malformations 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] 18 and of not all live-borns having undergone karyotyping but normal karyotype having been assumed on the basis of absence of stigmata of chromosomal anomaly at pediatric examination after birth. We are aware that among children that appeared phenotypically normal at birth, there might have 13 been some with an undetected chromosomal abnormality, e.g., Klinefelter's syndrome or Turner's syndrome. The exclusion of fetal loss with unknown karyotype may also have introduced some bias, because increased NT was less common (even though not statistically significantly so) among the fetal losses excluded than among the fetal losses included (the latter all having normal karyotype confirmed by genetic testing, the former all having unknown karyotype).
To sum up, we have calculated the magnitude of increase in risk of adverse outcome in fetuses with normal karyotype and increased NT using our own data but also using published raw data of other studies. Both in unselected populations and in high-risk populations increased NT ≥3 mm seems to increase the risk of malformation almost 10-fold and the risk of miscarriage about 5-fold. Larger NT increases the risks even more. We believe that this information may be useful when counselling patients, because it allows calculation of individual risks. The clinical consequence of our findings and those of others is that fetuses with increased NT, no signs of malformations at the NT scan, and normal or unknown karyotype should be thoroughly examined with regard to structural anomalies later in pregnancy when structural anomalies are more likely to be detectable than at the time of the NT scan. This is important, because prenatal diagnosis of some malformations -by enabling planning of perinatal management -might reduce postnatal mortality and morbidity 28 -32 .
How to convey the information to parents-to-be of a possible increased risk of spontaneous fetal loss in fetuses with increased NT but normal or unknown karyotype is a delicate matter, because the scientific basis for such information is rather weak (see above). However, it is important to bear in mind, that unless the background risk is very high, the odds of favourable outcome will be higher than those of adverse outcome. 2 18 of the 29 cases with major heart malformation had more than one cardio-vascular diagnosis 3 Two cases with associated anomalies Table 4 . Adverse outcome in fetuses with increased nuchal translucency and normal karyotype -summary of studies with a control group
